KAPLAN PHARMACOLOGY INTEGRATED COMPREHENSIVE EXAMINATION
Advanced Clinical Pharmacology Assessment - 200 Questions
SECTION A: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1-40
1. A 68-year-old male with hepatic cirrhosis is prescribed morphine for cancer pain.
Which pharmacokinetic parameter is MOST significantly altered in this patient?
A. Volume of distribution
B. Protein binding
C. Renal excretion
D. First-pass metabolism
Answer: D. First-pass metabolism
Rationale: Hepatic cirrhosis significantly reduces first-pass metabolism due to decreased
hepatic blood flow and functional hepatocyte mass. Morphine undergoes extensive first-
pass metabolism, and cirrhosis can increase oral bioavailability from 20% to 50-80%,
requiring dose reduction. Protein binding may be affected but is less clinically significant
than first-pass metabolism changes.
2. A drug with a half-life of 6 hours is administered intravenously. Approximately how
many hours will it take to reach 94% of steady-state concentration?
A. 12 hours
B. 24 hours
C. 30 hours
D. 36 hours
Answer: B. 24 hours
Rationale: Steady-state is achieved after approximately 4-5 half-lives. At 4 half-lives (24
hours), 94% of steady-state is reached. At 5 half-lives (30 hours), 97% is reached. The
formula is t = 4.32 × t½ for 95% steady-state. 6 hours × 4 = 24 hours for 94% achievement.
,3. Which of the following drug properties would result in the HIGHEST volume of
distribution?
A. High molecular weight
B. High protein binding
C. High lipophilicity
D. High ionization
Answer: C. High lipophilicity
Rationale: High lipophilicity allows extensive tissue penetration and accumulation,
resulting in large volume of distribution. Lipophilic drugs readily cross lipid membranes,
distribute into adipose tissue, and have Vd values exceeding total body water. High protein
binding limits distribution, while high ionization restricts tissue penetration.
4. A drug has a volume of distribution of 0.07 L/kg. This finding is MOST consistent
with:
A. Plasma compartment distribution
B. Extracellular fluid distribution
C. Total body water distribution
D. Tissue sequestration
Answer: A. Plasma compartment distribution
Rationale: A Vd of 0.07 L/kg corresponds to plasma volume (approximately 5% of body
weight or 0.05 L/kg). This indicates the drug is largely confined to the vascular
compartment, typically due to high molecular weight or extensive protein binding that
prevents extravascular distribution.
5. Which cytochrome P450 enzyme is responsible for the metabolism of the HIGHEST
percentage of clinically used drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Answer: D. CYP3A4
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and intestine,
metabolizing approximately 50% of all clinically used drugs. It is involved in the metabolism
,of numerous drugs including calcium channel blockers, statins, macrolides, and
benzodiazepines. CYP2D6 metabolizes about 25%, CYP2C9 about 15%, and CYP1A2 about
8%.
6. Grapefruit juice inhibits which of the following CYP enzymes, leading to increased
bioavailability of certain drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Answer: D. CYP3A4
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4. This inhibition reduces first-pass metabolism, significantly increasing oral
bioavailability of CYP3A4 substrates like simvastatin, nifedipine, and cyclosporine. The
effect persists for 24-72 hours and can lead to toxicity.
7. A patient with renal impairment has a serum creatinine of 3.0 mg/dL. Which
parameter would require the MOST significant dose adjustment?
A. Drug half-life
B. Volume of distribution
C. Protein binding
D. Bioavailability
Answer: A. Drug half-life
Rationale: Renal impairment directly prolongs the half-life of renally eliminated drugs. The
half-life is inversely proportional to clearance, and with reduced GFR, elimination half-life
increases significantly. Dose adjustment based on creatinine clearance is essential to
prevent accumulation and toxicity.
8. The therapeutic index of a drug is defined as:
A. LD50/ED50
B. ED50/LD50
C. TD50/ED50
D. ED50/TD50
, Answer: A. LD50/ED50
Rationale: The therapeutic index is the ratio of the median lethal dose (LD50) to the median
effective dose (ED50) in animal studies, or the toxic dose (TD50) to effective dose (ED50) in
humans. A higher TI indicates a wider margin of safety. Drugs with narrow TI (e.g., digoxin,
warfarin, lithium) require careful monitoring.
9. A drug with zero-order elimination kinetics demonstrates which of the following
characteristics?
A. Constant fraction of drug eliminated per unit time
B. Half-life remains constant regardless of dose
C. Clearance decreases at higher concentrations
D. Constant amount of drug eliminated per unit time
Answer: D. Constant amount of drug eliminated per unit time
Rationale: Zero-order kinetics means a constant amount of drug is eliminated per unit
time, regardless of concentration. This occurs when metabolic pathways are saturated.
Examples include phenytoin, aspirin (at high doses), and ethanol. The half-life increases
with dose in zero-order kinetics.
10. Which of the following is an example of an irreversible agonist?
A. Acetylcholine
B. Norepinephrine
C. Phenoxybenzamine
D. Isoproterenol
Answer: C. Phenoxybenzamine
Rationale: Phenoxybenzamine is an irreversible antagonist at alpha-adrenergic receptors,
forming covalent bonds. It does not act as an agonist. Irreversible agonists are relatively
rare; the classic example is phenoxybenzamine as an irreversible antagonist. Other
examples of irreversible drugs include omeprazole and organophosphates.
11. A drug that acts as a partial agonist at the mu-opioid receptor would:
A. Produce maximum effect similar to morphine
B. Produce submaximal effect even at full receptor occupancy
C. Antagonize the effects of full agonists
D. Produce no effect regardless of concentration
Advanced Clinical Pharmacology Assessment - 200 Questions
SECTION A: PHARMACOKINETICS AND PHARMACODYNAMICS
Questions 1-40
1. A 68-year-old male with hepatic cirrhosis is prescribed morphine for cancer pain.
Which pharmacokinetic parameter is MOST significantly altered in this patient?
A. Volume of distribution
B. Protein binding
C. Renal excretion
D. First-pass metabolism
Answer: D. First-pass metabolism
Rationale: Hepatic cirrhosis significantly reduces first-pass metabolism due to decreased
hepatic blood flow and functional hepatocyte mass. Morphine undergoes extensive first-
pass metabolism, and cirrhosis can increase oral bioavailability from 20% to 50-80%,
requiring dose reduction. Protein binding may be affected but is less clinically significant
than first-pass metabolism changes.
2. A drug with a half-life of 6 hours is administered intravenously. Approximately how
many hours will it take to reach 94% of steady-state concentration?
A. 12 hours
B. 24 hours
C. 30 hours
D. 36 hours
Answer: B. 24 hours
Rationale: Steady-state is achieved after approximately 4-5 half-lives. At 4 half-lives (24
hours), 94% of steady-state is reached. At 5 half-lives (30 hours), 97% is reached. The
formula is t = 4.32 × t½ for 95% steady-state. 6 hours × 4 = 24 hours for 94% achievement.
,3. Which of the following drug properties would result in the HIGHEST volume of
distribution?
A. High molecular weight
B. High protein binding
C. High lipophilicity
D. High ionization
Answer: C. High lipophilicity
Rationale: High lipophilicity allows extensive tissue penetration and accumulation,
resulting in large volume of distribution. Lipophilic drugs readily cross lipid membranes,
distribute into adipose tissue, and have Vd values exceeding total body water. High protein
binding limits distribution, while high ionization restricts tissue penetration.
4. A drug has a volume of distribution of 0.07 L/kg. This finding is MOST consistent
with:
A. Plasma compartment distribution
B. Extracellular fluid distribution
C. Total body water distribution
D. Tissue sequestration
Answer: A. Plasma compartment distribution
Rationale: A Vd of 0.07 L/kg corresponds to plasma volume (approximately 5% of body
weight or 0.05 L/kg). This indicates the drug is largely confined to the vascular
compartment, typically due to high molecular weight or extensive protein binding that
prevents extravascular distribution.
5. Which cytochrome P450 enzyme is responsible for the metabolism of the HIGHEST
percentage of clinically used drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Answer: D. CYP3A4
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and intestine,
metabolizing approximately 50% of all clinically used drugs. It is involved in the metabolism
,of numerous drugs including calcium channel blockers, statins, macrolides, and
benzodiazepines. CYP2D6 metabolizes about 25%, CYP2C9 about 15%, and CYP1A2 about
8%.
6. Grapefruit juice inhibits which of the following CYP enzymes, leading to increased
bioavailability of certain drugs?
A. CYP1A2
B. CYP2C9
C. CYP2D6
D. CYP3A4
Answer: D. CYP3A4
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4. This inhibition reduces first-pass metabolism, significantly increasing oral
bioavailability of CYP3A4 substrates like simvastatin, nifedipine, and cyclosporine. The
effect persists for 24-72 hours and can lead to toxicity.
7. A patient with renal impairment has a serum creatinine of 3.0 mg/dL. Which
parameter would require the MOST significant dose adjustment?
A. Drug half-life
B. Volume of distribution
C. Protein binding
D. Bioavailability
Answer: A. Drug half-life
Rationale: Renal impairment directly prolongs the half-life of renally eliminated drugs. The
half-life is inversely proportional to clearance, and with reduced GFR, elimination half-life
increases significantly. Dose adjustment based on creatinine clearance is essential to
prevent accumulation and toxicity.
8. The therapeutic index of a drug is defined as:
A. LD50/ED50
B. ED50/LD50
C. TD50/ED50
D. ED50/TD50
, Answer: A. LD50/ED50
Rationale: The therapeutic index is the ratio of the median lethal dose (LD50) to the median
effective dose (ED50) in animal studies, or the toxic dose (TD50) to effective dose (ED50) in
humans. A higher TI indicates a wider margin of safety. Drugs with narrow TI (e.g., digoxin,
warfarin, lithium) require careful monitoring.
9. A drug with zero-order elimination kinetics demonstrates which of the following
characteristics?
A. Constant fraction of drug eliminated per unit time
B. Half-life remains constant regardless of dose
C. Clearance decreases at higher concentrations
D. Constant amount of drug eliminated per unit time
Answer: D. Constant amount of drug eliminated per unit time
Rationale: Zero-order kinetics means a constant amount of drug is eliminated per unit
time, regardless of concentration. This occurs when metabolic pathways are saturated.
Examples include phenytoin, aspirin (at high doses), and ethanol. The half-life increases
with dose in zero-order kinetics.
10. Which of the following is an example of an irreversible agonist?
A. Acetylcholine
B. Norepinephrine
C. Phenoxybenzamine
D. Isoproterenol
Answer: C. Phenoxybenzamine
Rationale: Phenoxybenzamine is an irreversible antagonist at alpha-adrenergic receptors,
forming covalent bonds. It does not act as an agonist. Irreversible agonists are relatively
rare; the classic example is phenoxybenzamine as an irreversible antagonist. Other
examples of irreversible drugs include omeprazole and organophosphates.
11. A drug that acts as a partial agonist at the mu-opioid receptor would:
A. Produce maximum effect similar to morphine
B. Produce submaximal effect even at full receptor occupancy
C. Antagonize the effects of full agonists
D. Produce no effect regardless of concentration
